Apotex Corp, headquartered in Weston, Florida, is the U.S. subsidiary of Apotex Inc, the largest Canadian-owned pharmaceutical company. Apotex Inc. produces more than 300 generic pharmaceuticals in approximately 4,000 dosages and exports to 115 countries globally. The company has successfully secured FDA approval for over 230 ANDAs—and has averaged a new product launch every nine days for the last two years
Apotex Corp. has grown rapidly over that same time period, now boasting over a billion dollars in sales—and a new ranking in the top 10 generic pharmaceutical companies according to recent IMS HEALTH data. Apotex’s expansive product portfolio spans a wide range of dosage forms and therapeutic classes, including cardiovascular, anti-infectives, gastrointestinal, central nervous system, mental health, and pain management.
Commitment to Quality and Global Supply Chain Efficiencies
With state-of-the-art manufacturing facilities around the globe, Apotex’s highest priority is its Global Quality Program, which it considers integral to maintaining its strategic industry relationships. “Apotex attributes its success to being customer-centric and service-centric,” said Jeff Watson, president. “Our company maintains superior quality and efficiency by proactively optimizing processes throughout our supply chain.”
Apotex has recently quadrupled its manufacturing space, opening another large-volume manufacturing facility in Bangalore, India, in conjunction with its Signet and Etobicoke manufacturing facilities in Canada. Apotex also expanded into a new distribution facility in Indianapolis, Indiana, increasing its square footage by over 200 percent in order to meet the demands of its U.S. customers.
“Our company has exponentially grown since our inception 39 years ago,” says Watson. “We employ over 7,500 employees, and our group of companies occupies over four million square feet with state-of-the art technology to meet the needs of the world’s healthcare system.”
Investing for Tomorrow
New generic products are a critical component of Apotex’s growth. Apotex has historically reinvested close to 20 percent of its revenues in research and development. More importantly, Apotex is focused on more than simply developing new generics: the company is also working actively to develop a broad portfolio of biosimilars. As evidence of the company’s commitment to expanding innovative technology and drug delivery platform development, Apotex acquired a transdermal drug delivery systems company in 2012.
Reliable Advocate and Trusted Partner
Among generic manufacturers, Apotex stands alone in opposing anticompetitive patent settlements that delay generic competition, both by litigating against them and in advocating against them to the Federal Trade Commission and to Congress.
Apotex believes all manufacturers have a corporate citizenship responsibility to the global community. The company executes this responsibility through various national initiatives and partnerships. Apotex provides educational support to pharmacy students through a partnership with the NACDS Community Pharmacist Preceptor Program and supports the NACDS Foundation Pharmacy Partners Scholarship Program through a $1 million donation. Apotex partners with NCPA to support its Medication Return Program and continues to donate life-saving medicines to developing countries to alleviate human suffering and save the lives of thousands of people. Apotex is committed to serving the global community by advancing generics and providing high-quality, affordable products. For more information, visit www.apotexcorp.com